Department of Biomedical Engineering, University of Memphis, Memphis, TN, United States of America.
Department of Biomedical Engineering, University of Memphis, Memphis, TN, United States of America.
Int J Biol Macromol. 2019 Jul 15;133:372-381. doi: 10.1016/j.ijbiomac.2019.04.075. Epub 2019 Apr 12.
Advanced local delivery systems are needed as adjunctive treatments for severe injuries with high infection rates, such as open fractures. Chitosan systems have been investigated as antimicrobial local delivery systems for orthopaedic infection but possess mismatches between elution and degradation properties. Derivatives of chitosan were chosen that have enhanced swelling ratios or tailorable degradation properties. A combination of trimethyl chitosan and poly(ethylene glycol) diacrylate chitosan was developed as an injectable local delivery system. Research objectives were elution of antimicrobials for 7 days, degradation as open fractures heal, and cytocompatibility. The derivative combination eluted increased active concentrations of vancomycin and amikacin compared to the non-derivatized chitosan paste, 6 vs. 5 days and 5 vs. 4 days, respectively. The derivative combination degraded slower than non-derivatized paste in an enzymatic degradation study, 14 vs. 3 days, which increased antimicrobial delivery duration. Cytocompatibility of the combination with fibroblast and pre-osteoblast cells exceeds the cell viability standard set in ISO 10993-5. Combination paste requires an increased ejection force of 9.40 N (vs. 0.64 N), but this force was within an acceptable injection force threshold, 80 N. These preliminary results indicate combination paste should be further developed into a clinically useful adjunctive local delivery system for infection prevention.
需要先进的局部递送系统作为高感染率严重损伤的辅助治疗方法,例如开放性骨折。壳聚糖系统已被研究作为骨科感染的抗菌局部递送系统,但洗脱和降解特性之间存在不匹配。选择了壳聚糖的衍生物,具有增强的溶胀比或可定制的降解特性。将三甲基壳聚糖和聚(乙二醇)二丙烯酸酯壳聚糖组合开发为可注射的局部递送系统。研究目标是洗脱 7 天的抗菌剂、开放性骨折愈合时的降解以及细胞相容性。与未衍生化的壳聚糖糊剂相比,衍生物组合分别洗脱了 6 天和 5 天,分别增加了万古霉素和阿米卡星的有效浓度。在酶降解研究中,衍生物组合比未衍生化糊剂降解更慢,降解时间为 14 天,这增加了抗菌剂的递送时间。与成纤维细胞和前成骨细胞的组合糊剂的细胞相容性超过了 ISO 10993-5 中规定的细胞活力标准。组合糊剂需要增加 9.40 N 的推出力(而不是 0.64 N),但该力在可接受的注射力阈值 80 N 内。这些初步结果表明,组合糊剂应进一步开发为用于感染预防的临床有用的辅助局部递送系统。